Literature DB >> 7982330

Drug transfer across the placenta. Considerations in treatment and research.

C Simone1, L O Derewlany, G Koren.   

Abstract

Using the pregnant woman as a means to medicate her fetus represents a new and exciting therapeutic approach in clinical pharmacology. In years to come, we will see an increase in the use of the currently accepted fetal therapies and an increase in the number of therapies available to the caregiver or clinician aimed at assisting the unborn child. The pharmacologist, through in vitro research that aids our understanding of the role of the placenta in fetal drug therapy, can contribute to the growth of this new field within the realm of obstetric medicine.

Entities:  

Mesh:

Year:  1994        PMID: 7982330

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  5 in total

Review 1.  Fetal pharmacotherapy.

Authors:  Gideon Koren; Gil Klinger; Arne Ohlsson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Effect of pregnancy on emtricitabine pharmacokinetics.

Authors:  A M Stek; B M Best; W Luo; E Capparelli; S Burchett; C Hu; H Li; J S Read; A Jennings; E Barr; E Smith; S S Rossi; M Mirochnick
Journal:  HIV Med       Date:  2011-11-30       Impact factor: 3.180

3.  Acetylation of arylamines by the placenta.

Authors:  V A Smelt; H J Mardon; C W Redman; E Sim
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

4.  Cisapride use during human pregnancy: a prospective, controlled multicenter study.

Authors:  B Bailey; A Addis; A Lee; K Sanghvi; P Mastroiacovo; T Mazzone; M Bonati; C Paolini; H Garbis; T Val; C F De Souza; D Matsui; A S Schechtman; B Conover; M Lau; G Koren
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

5.  Pharmacokinetic examination of antipyrine passage through the placenta and the small intestine in rats.

Authors:  F Staud; Z Fendrich; O Jindrová
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.